New preclinical data supports immuno-oncology approach
Filed with ASX · · 5 pages · English
Earlier from Noxopharm
- New study further validates Noxopharms cancer pipeline
- Quarterly Activities/Appendix 4C Cash Flow Report
- SOF-SKN manufacturing begins to ensure clinical trial readi
- New data confirms cancer-fighting potential
- Noxopharms Sofra assets to be presented at global conference
Later from Noxopharm
- Appendix 4E - Preliminary Financial Report
- Novel oligonucleotides data presented at Options Conference
- Investor Presentation September 2026
- SOF-SKN to progress to extension study in CLE patients
- Audited Financial Statements
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm